Skip to main content

Table 1 Prognosis and prediction of response to immunotherapy in human cancer

From: Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy

Tumour type

Cell type

Sample number

Cell marker

Location of B cells

Clinical findings

Reference

Melanoma

B cells

136

CD20

Peritumoral TLS

Better response to ICIs

[75]

Melanoma

B cells

164

CD20

TLS

Improved OS

[58]

Sarcoma

B cells

496

CD20/CD20

TLS

Better response to ICIs

[76]

Breast cancer

B cells

1200

CD20

Intratumoural tissue

Improved DSS

[77]

Breast cancer (HER2+)

B cells

136

CD20

Intratumoural tissue

Prolonged OS and DFS

[78]

Breast cancer (TNBC)

B cells

113

CD20

Intratumoural tissue

Prolonged OS and DFS

[78]

Breast cancer (TNBC)

B cells

114

CD20/CD138

Intratumoural tissue

Improved DFS

[79]

Colorectal cancer

B cells

316

CD20

stromal

Improved DSS

[80]

Colorectal cancer

B cells

557

CD20/CD138

Intratumoural tissue

Improved OS

[81]

Gastric cancer

B cells

266

CD20

TLS

Improved OS

[82]

Gastric cancer

Bregs

59

CD19

/

Poorer OS

[39]

Hepatocellular carcinoma

B cells

120

CD20

Intratumoural tissue

Prolonged OS

[83]

Hepatocellular carcinoma

B cells

112

CD19/CD20

Intratumoural tissue

Improved survival rate

[84]

Pancreatic cancer

B cells

28

CD20

TLS

Improved OS

[56]

NSCLC

B cells

196

CD20

TLS

Improved DSS

[44]

NSCLC

PCs

207

CD20/CD138

Intratumoural tissue

Prolonged OS

[85]

Renal cell cancer

PCs

130

IgG+/IgA+

TLS

Prolonged PFS

[46]

Prostate cancer

B cells

110

CD20

Intratumoural tissue

Poorer RFS

[59]